Remove Compliance Remove Definition Remove FDA Remove Licensing
article thumbnail

From Discretion to Regulation: What FDA’s Final Rule Means for Laboratory Developed Tests

Hall Render

In April 2024, the Food and Drug Administration (“FDA”) issued a Final Rule amending the definition of in vitro diagnostics products (“IVDs”) found in 21 C.F.R. The FDA notes that it will continue to exercise enforcement discretion during the review of premarket submissions received by this stage.

FDA 40
article thumbnail

Is your Medicare Advantage Organization Ready for Compliance with Regulatory Changes in 2023?

Innovaare Compliance

MAOs have to ensure that TPMOs use a standardized disclaimer in their marketing materials that meet the definition of marketing whether they are in print, on the website, or in television advertising. If you have any questions, or you’d like to discuss these changes with one of our compliance experts, please call us at 1.408.850.2235.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Understanding the 2025 Medicare Part D Re-design: What You Need to Know

Innovaare Compliance

6] A compound drug not approved by the FDA under a New Drug Application or Biological License Application does not meet the definition of an applicable drug and will not be eligible for Part D. Rebates from the selected drugs may change. Additional drugs will be selected for negotiation every year after 2025. [6]

article thumbnail

SQA Regulatory Surveillance Summary 4 | Monthly Update 2021

SQA

The essential oils general monograph has been completely overhauled to expand, among others, the definition, production, test, and labelling sections, providing additional detail and clarification. FDA plant inspection and pay $50 million in fines and forfeiture. According to a recent CDCSO order , Notification S.O.

FDA 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

China’s Center for Medical Device Evaluation (CMDE) Update Compliance Guidelines and Recommended Paths for Clinical Evaluation Paths for Certain Medical Devices, 25 July 2022. 29 of 2022 , Technical Guidelines for Compliance with the Essential Principles of Medical Device Safety and Performance. CMDE Announcement No.

FDA 40
article thumbnail

Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives

Healthcare Law Blog

iii] The Act also authorizes the CT DCP to impose penalties for instances of non-compliance or violations of the Act. It remains to be seen whether subsequent regulations will further clarify the applicability of this law to certain individual roles that may not neatly fall within the Act’s definitions.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – March And April

SQA

The vote occurred on 16 February 2023 following a plenary meeting of the European Parliament, and represents a significant step towards a formal extension of MDR and IVDR compliance deadlines for some device manufacturers. The written procedure for recall was inadequate and this procedure had not been implemented.

FDA 40